Info
🌱來自: urothelial carcinoma
Management of Nonmuscle invasive UC
Depends on T stage & grade: TURBT, followed by either observation for low risk, or intravesical therapy w/ BCG or chemo (mitomycin or gemcitabine) (Eur Urol 2021;79(4):480; J Urol 2005;174(1):86; JNCI 2001;93(8):597) Strongly consider reresection if no muscle in TURBT specimen for accurate staging The majority (50-80%) of nonmuscle invasive dz will recur if treated by TURBT alone, w/ a proportion (20-25%) progressing to more invasive dz Cystectomy considered for residual T1, high-grade or muscle-invasion at reresection BCG: Unknown exact MOA, but triggers local immune response, given weekly × 6 wks followed by maintenance for 1-3 y based on risk status for relapse. Pembrolizumab: Given IV for pts with BCG-unresponsive CIS ± papillary dz who were ineligible for or declined radical cystectomy (Lancet Onc 2021;22:919-930) Surveillance: Cystoscopy & urine cytology ∼3 mos, can be spaced if no recurrent dz
Siblings
- Epidemiology-of-urothelial carcinoma
- Etiology and clinical manifestations-of-urothelial carcinoma
- Pathologic Subtypes-of-urothelial carcinoma
- Workup-of-urothelial carcinoma
- Staging and prognosis-of-urothelial carcinoma
- Management of Nonmuscle invasive UC
- Management of Muscle invasive UC
- Management Metastatic UC
- Cancers of the renal pelvis and ureter
- Molecular biology and targeted therapy-of-urothelial carcinoma